Vmn1r196 inhibitors belong to a specialized class of chemical compounds designed to modulate the activity of the Vmn1r196 receptor, a member of the vomeronasal receptor family. These receptors are part of the broader family of G protein-coupled receptors (GPCRs), which are involved in the detection of pheromones and other signaling molecules. The Vmn1r196 receptor, specifically, is known for its role in sensory processes related to chemical communication in various organisms. Inhibitors of Vmn1r196 are typically structured to bind selectively to this receptor, preventing it from interacting with its natural ligands or signaling partners. This class of compounds is of interest due to their ability to alter receptor-ligand interactions in controlled environments, which can lead to better understanding of Vmn1r196's role in chemosensory pathways.
These inhibitors are often characterized by their diverse chemical structures, which include small molecules with specific affinity for the receptor. The development of these inhibitors involves identifying key molecular features that allow for high binding specificity, typically through hydrophobic interactions, hydrogen bonding, or other non-covalent forces. Additionally, research into the physicochemical properties of Vmn1r196 inhibitors, such as their solubility, stability, and molecular weight, is important to ensure that they maintain effective interaction with the receptor. These properties can vary widely, depending on the specific inhibitor in question, making the design and synthesis of these compounds a significant area of interest within chemical research fields.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, can affect noradrenergic signaling potentially related to Vmn1r196. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist, can modulate GPCR signaling potentially affecting Vmn1r196. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, can alter GPCR-mediated processes potentially impacting Vmn1r196. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, can affect GPCR signaling pathways potentially influencing Vmn1r196. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, can modulate GPCR pathways potentially related to Vmn1r196 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, can affect calcium signaling pathways potentially related to Vmn1r196. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, can affect GPCR-mediated signaling pathways involved with Vmn1r196. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, can indirectly influence signaling mechanisms relevant to Vmn1r196. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, can affect downstream signaling pathways that could impact Vmn1r196 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, can influence GPCR-mediated signaling pathways related to Vmn1r196. | ||||||